Bioxyne Secures €3.2M Contract to Supply 1,600kg Medical Cannabis in Germany
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.
- Minimum 1,600 kg supply of GMP-certified medical cannabis flower to Germany
- Partnership with Farmakem d.o.o. and Adrex Pharmaceuticals GmbH
- 14 cannabis strains registered with Germany’s BfArM authority
- First shipments scheduled for September and November 2025
- Strategic expansion into Europe’s fastest-growing medical cannabis market
Bioxyne’s Strategic Entry into Germany
Bioxyne Limited (ASX, BXN), via its wholly owned subsidiary Breathe Life Sciences (BLS), has taken a decisive step into the German medical cannabis market by signing a manufacture and supply agreement worth a minimum of €3.2 million (A$5.6 million) for the 2026 financial year. This deal commits BLS to supply at least 1,600 kilograms of GMP-certified medical cannabis flower to Farmakem d.o.o., with distribution managed by Adrex Pharmaceuticals GmbH, a leading German cannabis importer and wholesaler.
Germany’s medical cannabis market has seen rapid growth following deregulation in early 2025, positioning it to surpass Australia’s $1 billion annual market by 2026. Cannabis flower accounts for over 95% of medical cannabis sales in Germany, making BLS’s GMP certification a critical competitive advantage. The agreement not only opens a new revenue stream but also establishes Bioxyne’s footprint in Europe’s largest medical cannabis market.
Regulatory Approvals and Market Readiness
Central to this expansion is the registration of 14 Australian-manufactured cannabis strains with Germany’s Federal Institute for Drugs and Medical Devices (BfArM), the country’s primary drug approval authority. This regulatory endorsement authorizes the import and distribution of BLS’s products, smoothing the path for market entry and compliance.
The first shipment of 580 kilograms is scheduled for September 2025, followed by a second delivery in November, signaling a well-paced rollout. BLS and Adrex are also collaborating to establish the Dr Watson® brand in Germany, leveraging an internationally recognized name in cannabis-based health products.
Broader Growth Prospects
Beyond Germany, Bioxyne is targeting further growth in FY2026 through expansion in Australia and new markets including the UK and other European countries. BLS’s multinational operations span Australia, Japan, the UK, and Europe, with a diversified portfolio that includes medicinal cannabis, MDMA, and psilocybin products.
This agreement underscores Bioxyne’s strategy of leveraging GMP certification and international partnerships to scale its manufacturing and distribution capabilities. As the medical cannabis sector evolves globally, Bioxyne’s positioning in high-growth markets could translate into sustained revenue growth and enhanced shareholder value.
Bottom Line?
Bioxyne’s German market entry marks a pivotal expansion, setting the stage for broader European growth and increased revenue streams in FY2026.
Questions in the middle?
- How will Bioxyne manage competitive pressures in Germany’s rapidly expanding cannabis market?
- What are the margins and profitability expectations tied to this supply agreement?
- Could regulatory changes in Germany or the EU impact Bioxyne’s growth trajectory?
